Furthermore, multiple phase I and II clinical trials have demonstrated the efficacy of MEK inhibitors (selumetinib, mirdametinib, trametinib, and binimetinib) in the treatment of PNF, resulting in tumor shrinkage, functional benefits, and improvement in patient-reported outcome measures, including pain and quality of life [47,48,49,50,51]. This evidence concerns the gene MAP2K7 and neoplasm.